Literature DB >> 29700852

LC-MS/MS method for the simultaneous determination of tenofovir, emtricitabine, elvitegravir and rilpivirine in dried blood spots.

Pavan Kumar Prathipati1, Subhra Mandal1, Christopher J Destache1.   

Abstract

A simple, short, and rugged LC-MS/MS method for the simultaneous determination of tenofovir, emtricitabine, elvitegravir and rilpivirine was developed and validated. Dried blood spots were prepared with 25 μL of spiked whole blood. A 3 mm punch was extracted with methanol containing labeled internal standards. Ten microliters was injected into the LC-MS/MS using isocratic mobile phase composed of 0.1% formic acid in water and 0.1% formic acid in acetonitrile (45: 55 v/v) at a flow rate of 0.25 mL/min. The method was validated in the range of 10-2000 ng/mL for all four analytes. The intra-assay accuracy (RE) of the method was -4.73-4.78, 1.35-2.89, -8.89 to -0.49 and - 1.40-1.81 for tenofovir, emtricitabine, elvitegravir and rilpivirine, respectively. The inter-assay accuracy was within ±15% of nominal and precision (CV) was <15%. The hematocrit effect on quantification was nonsignificant at the tested hematocrit levels (35-70%). The dried blood spot method showed good agreement with the plasma method, and hence can be used as an alternative to plasma method.
Copyright © 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  antiretrovirals; dried blood spot; mass spectrometry; plasma

Year:  2018        PMID: 29700852      PMCID: PMC6203670          DOI: 10.1002/bmc.4270

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  16 in total

1.  High efficacy of first-line ART in a West African cohort, assessed by dried blood spot virological and pharmacological measurements.

Authors:  Pierre de Truchis; Minh Patrick Lê; Mamane Daou; Boubacar Madougou; Yacouba Nouhou; Sahada Moussa Saley; Achirou Sani; Eric Adehossi; Elisabeth Rouveix; Mamadou Saidou; Gilles Peytavin; Constance Delaugerre
Journal:  J Antimicrob Chemother       Date:  2016-07-20       Impact factor: 5.790

2.  Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method.

Authors:  Neil Spooner; Rakesh Lad; Matt Barfield
Journal:  Anal Chem       Date:  2009-02-15       Impact factor: 6.986

3.  Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue.

Authors:  Teresa L Parsons; Mark A Marzinke
Journal:  J Pharm Biomed Anal       Date:  2016-09-04       Impact factor: 3.935

4.  Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models.

Authors:  Maïlys De Sousa Mendes; Deborah Hirt; Cécile Vinot; Elodie Valade; Gabrielle Lui; Claire Pressiat; Naïm Bouazza; Frantz Foissac; Stephane Blanche; Minh Patrick Lê; Gilles Peytavin; Jean-Marc Treluyer; Saik Urien; Sihem Benaboud
Journal:  Br J Clin Pharmacol       Date:  2016-01-12       Impact factor: 4.335

Review 5.  Current status and prospects of HIV treatment.

Authors:  Tomas Cihlar; Marshall Fordyce
Journal:  Curr Opin Virol       Date:  2016-03-28       Impact factor: 7.090

6.  The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma.

Authors:  Sujan Dilly Penchala; Sandra Fawcett; Laura Else; Deirdre Egan; Alieu Amara; Emilie Elliot; Elizabeth Challenger; David Back; Marta Boffito; Saye Khoo
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-05-27       Impact factor: 3.205

7.  Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS.

Authors:  Jia-Hua Zheng; Louis A Guida; Caitlin Rower; Jose Castillo-Mancilla; Amie Meditz; Brandon Klein; Becky Jo Kerr; Jacob Langness; Lane Bushman; Jennifer Kiser; Peter L Anderson
Journal:  J Pharm Biomed Anal       Date:  2013-08-31       Impact factor: 3.935

8.  Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California.

Authors:  Raphael J Landovitz; Matthew Beymer; Ryan Kofron; Kathy Rivet Amico; Christina Psaros; Lane Bushman; Peter L Anderson; Risa Flynn; David P Lee; Robert K Bolan; Wilbert C Jordan; Chi-Hong Tseng; Rhodri Dierst-Davies; Jim Rooney; Amy Rock Wohl
Journal:  J Acquir Immune Defic Syndr       Date:  2017-12-15       Impact factor: 3.731

9.  The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards.

Authors:  Tom Delahunty; Lane Bushman; Brian Robbins; Courtney V Fletcher
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-05-21       Impact factor: 3.205

10.  A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.

Authors:  Manel Aouri; Alexandra Calmy; Bernard Hirschel; Amalio Telenti; Thierry Buclin; Matthias Cavassini; Andri Rauch; Laurent A Decosterd
Journal:  J Mass Spectrom       Date:  2013-05       Impact factor: 1.982

View more
  2 in total

1.  Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.

Authors:  Perrine Courlet; Susana Alves Saldanha; Matthias Cavassini; Catia Marzolini; Eva Choong; Chantal Csajka; Huldrych F Günthard; Pascal André; Thierry Buclin; Vincent Desfontaine; Laurent Arthur Decosterd
Journal:  J Mass Spectrom       Date:  2020-03-11       Impact factor: 1.982

Review 2.  Detection and quantification of Covid-19 antiviral drugs in biological fluids and tissues.

Authors:  Maria A Acquavia; Luca Foti; Raffaella Pascale; Antonia Nicolò; Vincenzo Brancaleone; Tommaso R I Cataldi; Giuseppe Martelli; Laura Scrano; Giuliana Bianco
Journal:  Talanta       Date:  2020-11-05       Impact factor: 6.057

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.